Island Pharmaceuticals LtdASX: ILA

Island Bolsters US Biodefence Readiness Ahead of Trials

· Issued by Island Pharmaceuticals Ltd

Filed with ASX · · 4 pages · English

Summary by 6ix AI

Island Pharmaceuticals Ltd has announced an expansion of its engagement in the US biodefence sector, particularly ahead of its planned studies for Galidesivir under the FDA Animal Rule. Island is also increasing its involvement with the Medical Countermeasures Coalition, focusing on research and procurement initiatives related to biodefence. The company is on track to commence dose optimisation studies for Galidesivir, aimed at treating Marburg Virus Disease, in the upcoming quarter.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Island Pharmaceuticals Ltd on 6ix

Earlier from Island Pharmaceuticals

Later from Island Pharmaceuticals

All Island Pharmaceuticals news releases